“We had less waiting to do between elements of work. But we still followed the normal regulatory pathway.
“Yes, we did it quickly, but we didn’t miss any steps out.
“It is frustrating when people say development was too fast without saying why that would be.”
With the coronavirus rapidly crossing borders and infecting tens of millions of people, many of the bureaucratic processes that bogged down vaccine development in the past were thrown out the window.
Vaccine developers were still held up to a high standard and had to clear all the regulatory hurdles before their products were approved for human use – but they were allowed to do so at a much faster pace than normal.
The streamlined process allowed the Moderna, AstraZeneca and Pfizer vaccines to be approved in late 2020 to early 2021.